Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
2023年8月23日 - 7:50PM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced the acceptance
of three abstracts for presentation at the HAEi Regional Conference
EMEA, taking place in Munich from September 1-3, 2023.
Presentation details:
- Title: Early symptom relief following
treatment with the oral bradykinin 2 receptor antagonist
deucrictibant immediate-release capsule (PHVS416) in patients with
hereditary angioedema attacksPresenter: Marcin
Stobiecki, M.D.Date, Time: Friday, September 1,
19:15-20:15 CESTFormat: Poster Presentation
- Title: Efficacy and safety of bradykinin B2
receptor antagonism with oral deucrictibant in prophylaxis of
hereditary angioedema attacks: CHAPTER-1 phase 2 trial
designPresenter: Emel Aygören-Pürsün,
M.D.Date, Time: Friday, September 1, 19:15-20:15
CESTFormat: Poster Presentation
- Title: Efficacy and safety of the oral
bradykinin B2 receptor antagonist deucrictibant immediate-release
capsule (PHVS416) in treatment of hereditary angioedema attacks:
results of RAPIDe-1 phase 2 trialPresenter: Markus
Magerl, M.D.Date, Time: Saturday, September 2,
11:35-12:45 CESTFormat: Oral Presentation
After the close of the respective sessions, the posters and
presentation slides will be made available on the Investors section
of the Pharvaris website at:
https://ir.pharvaris.com/news-events/events-presentations.
About PharvarisBuilding on its deep-seated
roots in HAE, Pharvaris is a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks. By directly pursuing this clinically proven
therapeutic target with novel small molecules, the Pharvaris team
aspires to offer people with all sub-types of HAE efficacious,
safe, and easy-to-administer alternatives to treat attacks, both
on-demand and prophylactically. The company brings together the
best talent in the industry with deep expertise in rare diseases
and HAE. For more information, visit https://pharvaris.com/.
Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
Maggie.beller@pharvaris.com
Pharvaris NV (NASDAQ:PHVS)
過去 株価チャート
から 4 2024 まで 5 2024
Pharvaris NV (NASDAQ:PHVS)
過去 株価チャート
から 5 2023 まで 5 2024